Media Coverage

Media Coverage

Read how VistaGen’s intention to revolutionize mental health medicine is causing a buzz in the media.

Cheddar logo image
Seeking a Cure: VistaGen Therapeutics' Potential Anti-Depression Drug
Read
BioSpace logo image
BioSpace's Global Biopharma Roundup: February 21
Read
Fox Business 1 logo image
J&J nears FDA approval for landmark depression drug to replace ketamine treatments
Read
Informatics logo image
Can We Treat Mood Disorders with Pharmacological Therapeutics?
Read
BioSpace logo image
Exclusive Interview: VistaGen CEO Is Passionate About Developing New Treatments for Depression
Read
Thepharmaletter logo image
VistaGen CEO notes broad market potential of ketamine-like AV-101
Read
San Francisco Business Times logo image
Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more
Read
PharmaTimes logo image
Company focus: VistaGen
Read
DDNews1 logo image
VistaGen acquires worldwide license of phase 3-ready CNS drug
Read